Muscle-invasive bladder cancer (muscle invasive bladder cancer, MIBC) is an aggressive bladder cancer subtype and a disease context often associated with poor prognosis. It is used in biomarker studies to evaluate prognosis and therapeutic response, including multi-cohort analyses such as muscle invasive bladder cancer-related MTHFD1L work. Clinically, it is a major immunotherapy setting: durvalumab has been FDA approved for adult patients with this disease, and immune-checkpoint inhibitors have shown promising therapeutic potential. Neoadjuvant immunotherapy has also been studied in cisplatin-ineligible patients, including nivolumab with or without ipilimumab. Recent literature highlights both regulatory progress and ongoing trial development in this high-risk disease area.
Biomarkers and Prognosis
- MIBC was the disease context for a multi-cohort study of muscle invasive bladder cancer prognosis and therapeutic response biomarkers, focusing on MTHFD1L. (PMID:41981612)
- The disease is described as an aggressive bladder cancer subtype and is often associated with poor prognosis. (PMID:41981612)
- Biomarker evaluation in MIBC was framed around prognosis and treatment-response assessment. (PMID:41981612)
Immunotherapy and Approved Treatments
- durvalumab was FDA approved for adult patients with MIBC. (PMID:41678313)
- Immune-checkpoint-inhibitors have shown promising therapeutic potential in MIBC. (PMID:41678313)
- The FDA approval summary for durvalumab specifically addressed treatment of adult patients with MIBC. (PMID:41678313)
Neoadjuvant Therapy
- nivolumab was evaluated as neoadjuvant therapy for cisplatin-ineligible patients with MIBC. (PMID:41627171)
- ipilimumab was studied in combination with neoadjuvant nivolumab for cisplatin-ineligible patients with MIBC. (PMID:41627171)
- The neoadjuvant trial focused on patients unable to receive cisplatin, a clinically important subgroup in MIBC. (PMID:41627171)